Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modeling analysis based on a nationwide cohort study. - Banerjee, A; Lane, D; Torp-Pedersen, C (Thromb Haemost, 2012)